Thalidomide Analogues and Their Anti-Angiogenic Activity
Author Information
Author(s): Dredge K, Marriott J B, Macdonald C D, Man H-W, Chen R, Muller G W, Stirling D, Dalgleish A G
Primary Institution: St. George's Hospital Medical School
Hypothesis
The study aims to assess the anti-angiogenic activity of thalidomide analogues and their relationship to immunomodulatory effects.
Conclusion
The study found that thalidomide analogues exhibit significant anti-angiogenic activity that is independent of their immunomodulatory properties.
Supporting Evidence
- IMiD-1 and SelCID-1 significantly inhibited angiogenesis even at low concentrations.
- Thalidomide showed minimal effects in the rat model, while the analogues were more potent.
- IMiD-1 significantly reduced tumor growth rates in nude mice.
Takeaway
This study shows that new versions of thalidomide can help stop cancer by blocking the growth of blood vessels that feed tumors.
Methodology
The study used in vitro assays to evaluate the anti-angiogenic effects of thalidomide analogues on endothelial cells and in vivo models to assess tumor growth.
Potential Biases
Potential bias in the selection of analogues and the assays used to measure outcomes.
Limitations
The study primarily focuses on specific analogues and may not represent the full range of thalidomide derivatives.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website